Chai Discovery has secured $400 million in Series C funding, bringing its valuation to $3.8 billion and marking a significant follow-on round. The company, which uses AI to predict biochemical molecule interactions, plans to use these funds to accelerate its antibody discovery platform. The round was led by Index Ventures and included participation from Kleiner Perkins, Sequoia Capital, Dimension, and Bain Capital Ventures.